B. Gérard

587 total citations
31 papers, 444 citations indexed

About

B. Gérard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, B. Gérard has authored 31 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in B. Gérard's work include Cancer Treatment and Pharmacology (7 papers), Gastric Cancer Management and Outcomes (6 papers) and Cancer therapeutics and mechanisms (4 papers). B. Gérard is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Gastric Cancer Management and Outcomes (6 papers) and Cancer therapeutics and mechanisms (4 papers). B. Gérard collaborates with scholars based in Belgium, France and Italy. B. Gérard's co-authors include Harry Bleiberg, Steinar Aamdal, Maurizio D’Incalci, B. Giroux, Philippe B. Bertrand, Catherine Lucas, Serge Leyvraz, J. P. Bizzari, Jean-Pierre Bizzari and Christophe Ravoet and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

B. Gérard

30 papers receiving 434 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Gérard Belgium 15 191 158 97 72 49 31 444
Gunther Guetens Belgium 12 200 1.0× 167 1.1× 154 1.6× 116 1.6× 21 0.4× 27 615
Aya Nakaya Japan 13 290 1.5× 102 0.6× 131 1.4× 71 1.0× 61 1.2× 54 601
Devron R. Shah United Kingdom 7 241 1.3× 190 1.2× 187 1.9× 48 0.7× 36 0.7× 8 599
Lisa A. Raedler 14 307 1.6× 185 1.2× 57 0.6× 95 1.3× 63 1.3× 53 649
D. J. Theo Wagener Netherlands 13 240 1.3× 170 1.1× 158 1.6× 21 0.3× 45 0.9× 44 543
Greta Cipriani Italy 7 325 1.7× 166 1.1× 87 0.9× 69 1.0× 36 0.7× 7 529
Merry Tetef United States 14 269 1.4× 147 0.9× 119 1.2× 78 1.1× 30 0.6× 29 581
Jenny Zheng United States 13 315 1.6× 143 0.9× 124 1.3× 34 0.5× 23 0.5× 26 634
Rajendra Pradhan United States 14 131 0.7× 200 1.3× 121 1.2× 105 1.5× 39 0.8× 33 795
M Fukushima Japan 9 341 1.8× 159 1.0× 238 2.5× 26 0.4× 40 0.8× 37 639

Countries citing papers authored by B. Gérard

Since Specialization
Citations

This map shows the geographic impact of B. Gérard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Gérard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Gérard more than expected).

Fields of papers citing papers by B. Gérard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Gérard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Gérard. The network helps show where B. Gérard may publish in the future.

Co-authorship network of co-authors of B. Gérard

This figure shows the co-authorship network connecting the top 25 collaborators of B. Gérard. A scholar is included among the top collaborators of B. Gérard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Gérard. B. Gérard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berthou, J., et al.. (2019). Sécurisation du parcours de soins du sujet âgé : intérêt d’une offre variée d’activités pharmaceutiques ?. Annales Pharmaceutiques Françaises. 77(3). 222–231. 5 indexed citations
2.
Gérard, B. & Harry Bleiberg. (2004). Treatment of hepatocarcinoma. Current Oncology Reports. 6(3). 184–191. 12 indexed citations
3.
Pivot, Xavier, Ahmad Awada, D Gedouin, et al.. (2003). Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer. Annals of Oncology. 14(3). 373–377. 8 indexed citations
4.
Awada, Ahmad, Sylvie Giacchetti, B. Gérard, et al.. (2002). Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules. Annals of Oncology. 13(12). 1925–1934. 9 indexed citations
5.
Stupp, Roger, Jean Bauer, Olivia Pagani, et al.. (1998). Ventricular arrhythmia and torsade de pointe: Dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Annals of Oncology. 9(11). 1233–1242. 21 indexed citations
6.
Aamdal, Steinar, et al.. (1998). Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. Melanoma Research. 8(6). 565–572. 5 indexed citations
7.
Gérard, B., et al.. (1998). Oxaliplatin combined to 5-fluorouracil and folinic acid. Anti-Cancer Drugs. 9(4). 301–306. 20 indexed citations
8.
Tueni, Elias, A. Van Oosterom, Ad Backx, et al.. (1997). Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. British Journal of Cancer. 76(10). 1376–1381. 16 indexed citations
9.
Bleiberg, Harry, B. Gérard, J. Wils, et al.. (1997). Gastrointestinal Tract Cancer Liaison Office: An attempt to organise clinical research in Europe. European Journal of Cancer. 33(10). 1536–1545.
10.
Bleiberg, Harry, et al.. (1997). [Role of radiotherapy in cancers of the stomach].. PubMed. 84(9). 913–6. 2 indexed citations
11.
12.
Lu, D S, S Saini, P F Hahn, et al.. (1994). T2-weighted MR imaging of the upper part of the abdomen: should fat suppression be used routinely?. American Journal of Roentgenology. 162(5). 1095–1100. 40 indexed citations
13.
Khayat, David, B. Giroux, J. Bérille, et al.. (1994). Fotemustine in the Treatment of Brain Primary Tumors and Metastases. Cancer Investigation. 12(4). 414–420. 56 indexed citations
14.
Ravoet, Christophe, Harry Bleiberg, & B. Gérard. (1993). Non-surgical treatment of hepatocarcinoma. Journal of Surgical Oncology. 53(S3). 104–111. 22 indexed citations
15.
Bleiberg, Harry, B. Gérard, & Philippe Deguiral. (1992). Adjuvant therapy in resectable gastric cancer. British Journal of Cancer. 66(6). 987–991. 17 indexed citations
16.
17.
Merimsky, Ofer, Moshe Inbar, B. Gérard, & Samario Chaitchik. (1992). Fotemustine — an advance in the treatment of metastatic malignant melanoma. Melanoma Research. 2(5). 401–406. 10 indexed citations
18.
Calabresi, F., Matti Aapro, D. Becquart, et al.. (1991). Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma. Annals of Oncology. 2(5). 377–378. 32 indexed citations
19.
Bleiberg, Harry, B. Gérard, P Peetrons, & P. Dodion. (1989). Measurements of response to chemotherapy using ultrasound in metastatic liver involvement. European Journal of Cancer and Clinical Oncology. 25(5). 857–859. 4 indexed citations
20.
Dodion, P., et al.. (1987). Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015). European Journal of Cancer and Clinical Oncology. 23(6). 837–842. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gunther Guetens Breakdown of academic impact, for papers by Aya Nakaya Breakdown of academic impact, for papers by Devron R. Shah Breakdown of academic impact, for papers by Lisa A. Raedler Breakdown of academic impact, for papers by D. J. Theo Wagener Breakdown of academic impact, for papers by Greta Cipriani Breakdown of academic impact, for papers by Merry Tetef Breakdown of academic impact, for papers by Jenny Zheng Breakdown of academic impact, for papers by Rajendra Pradhan Breakdown of academic impact, for papers by M Fukushima
Rankless by CCL
2026